Top ▲

Celiac disease

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1031
Name:Celiac disease
Associated with:3 targets
1 immuno-relevant ligand
Database Links
Disease Ontology: DOID:10608

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols
CIITA
NLRP1
regulator of G-protein signaling 1
References:  1-9

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
petesicatib
Immuno Disease Comments: Completed Phase 1 evaluation in celiac patients- see NCT02679014.
Clinical Use: (RO5459072 or RG7625) has completed Phase 2 clinical evaluation in Sjögren's syndrome (NCT02701985) and Phase 1 in celiac disease (NCT02679014), but there are no active clinical trials registered with ClinicalTrials.gov. | View clinical data
Bioactivity Comments: Petesicatib (RO5459072) is selective for cathepsin S compared to other cathepsin isozymes examined [10]. | View biological activity

References

Show »

1. Amundsen SS, Rundberg J, Adamovic S, Gudjónsdóttir AH, Ascher H, Ek J, Nilsson S, Lie BA, Naluai AT, Sollid LM. (2010) Four novel coeliac disease regions replicated in an association study of a Swedish-Norwegian family cohort. Genes Immun, 11 (1): 79-86. [PMID:19693089]

2. Gibbons DL, Abeler-Dörner L, Raine T, Hwang IY, Jandke A, Wencker M, Deban L, Rudd CE, Irving PM, Kehrl JH et al.. (2011) Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential. J Immunol, 187 (5): 2067-71. [PMID:21795595]

3. Guo CC, Wang M, Cao FD, Huang WH, Xiao D, Ye XG, Ou ML, Zhang N, Zhang BH, Liu Y et al.. (2016) Meta-Analysis on Associations of RGS1 and IL12A Polymorphisms with Celiac Disease Risk. Int J Mol Sci, 17 (4). [PMID:27043536]

4. Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M, Romanos J, Dinesen LC, Ryan AW, Panesar D et al.. (2008) Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet, 40 (4): 395-402. [PMID:18311140]

5. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z et al.. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 476 (7359): 214-9. [PMID:21833088]

6. Izzo V, Pinelli M, Tinto N, Esposito MV, Cola A, Sperandeo MP, Tucci F, Cocozza S, Greco L, Sacchetti L. (2011) Improving the estimation of celiac disease sibling risk by non-HLA genes. PLoS ONE, 6 (11): e26920. [PMID:22087237]

7. Plaza-Izurieta L, Castellanos-Rubio A, Irastorza I, Fernández-Jimenez N, Gutierrez G, CEGEC, Bilbao JR. (2011) Revisiting genome wide association studies (GWAS) in coeliac disease: replication study in Spanish population and expression analysis of candidate genes. J Med Genet, 48 (7): 493-6. [PMID:21490378]

8. Romanos J, Barisani D, Trynka G, Zhernakova A, Bardella MT, Wijmenga C. (2009) Six new coeliac disease loci replicated in an Italian population confirm association with coeliac disease. J Med Genet, 46 (1): 60-3. [PMID:18805825]

9. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, Howson JM, Stevens H, McManus R, Wijmenga C et al.. (2008) Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med, 359 (26): 2767-77. [PMID:19073967]

10. Tato M, Kumar SV, Liu Y, Mulay SR, Moll S, Popper B, Eberhard JN, Thomasova D, Rufer AC, Gruner S et al.. (2017) Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury. Sci Rep, 7 (1): 2775. [PMID:28584258]